Trial Profile

A phase 2/3 trial assessing odiparcil in pediatric MPS VI patients

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 23 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odiparcil (Primary)
Indications Mucopolysaccharidosis VI
Focus Registrational; Therapeutic Use
Sponsors Inventiva Pharma

Most Recent Events

23 Sep 2022 New trial record
22 Sep 2022 According to Inventiva Pharma media release, the company received FDA feedback that odiparcil can be dosed in pediatric MPS VI patients and that this single phase II/III trial design presented by the Company could potentially support a future odiparcil marketing application

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com